Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the satisfaction of customary closing conditions.
Related news for (BLPH)
- Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
- Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
- Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
- Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
- Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results